- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02888756
iHIVARNA Clinical Trial in HIV Infected Individuals (iHIVARNA-01)
A Phase IIa Randomized, Placebo Controlled, Double Blinded Study to Evaluate the Safety and Immunogenicity of iHIVARNA-01 in Chronically HIV-infected Patients Under Stable Combined Antiretroviral Therapy
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Objective: To evaluate the safety and immunogenicity of iHIVARNA-01 as a new therapeutic vaccine in HIV infected patients.
Study design and duration: Phase IIa, multicentre double-blind placebo controlled intervention study. Each patient will be followed for 30 weeks. The study duration will be 38 weeks from inclusion of the first patient.
Sites: Erasmus MC, Rotterdam The Netherlands (sponsor), Hospital Clínic de Barcelona and Institut de Recerca de la Sida - Caixa, Barcelona, Spain, Instituut voor Tropische Geneeskunde Antwerp, Belgium and Vrije Universiteit Brussel/UZ Brussel, Belgium
Study population: Chronically HIV-1- infected patients under stable cART with plasma viral load (pVL) ≤ 50 copies/ml and stable CD4+ T-cell counts ≥ 450/μl, aged 18 years or above.
Sample size: after recruitment and screening, 70 patients will be included and randomized to one of the study-arms.
Intervention: One group (n=40) receives the HIVACAT-TriMix (300 microgram TriMix + 900 microgram HIVACAT) vaccine intranodally on three occasions with a two-week interval. One control group (n=15) receives TriMix only (300 microgram TriMix) and one group (n=15) receives saline intranodally on three occasions with a two-week interval. Two weeks after the last vaccination cART treatment will be interrupted. If plasma virus is detectable, cART will be re-initiated twelve weeks after treatment interruption. cART can always be re-initiated for medical reasons, as judged by the clinical investigator.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Antwerp, Belgium
- Institute for Tropical Medicine
-
Brussels, Belgium
- UZ Brussel
-
-
-
-
-
Rotterdam, Netherlands
- Erasmus MC
-
-
-
-
-
Badalona, Spain
- Hospital Universitari Germans Trias i Pujol
-
Barcelona, Spain
- Hospital Clinic
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- ≥ 18 years of age;
- Voluntarily signed informed consent;
- Proven HIV-1 infection (with documented antibodies against HIV-1 and a detectable plasma HIV-1 RNA before initiation of therapy);
- On stable treatment with cART regimen (antiretroviral therapy consisting of at least three registered antiretroviral agents) for at least 3 years;
- Nadir CD4+ ≥ 350 cells/μl (up to 2 occasional determinations ≤ 350 cells/μl are allowed);
- Current CD4+ cell count ≥ 450 cells/μl;
- HIV-RNA below 50 copies/mL in the last 6 months prior to randomization, during at least two measurements (occasional so called 'blips' ≤ 500 copies/mL are permitted);
If sexually active, willing to use a reliable method of reducing the risk of transmission to their sexual partners during treatment interruption (including PrEP).
- For heterosexually active female, using an effective method of contraception with partner (combined oral contraceptive pill; injectable or implanted contraceptive; IUD/IUS; consistent record with condoms; physiological or anatomical sterility (in self or partner) from 14 days prior to the first vaccination until 4 months after the last vaccination.
For heterosexually active male, using an effective method of contraception with their partner from the first day of vaccination until 4 months after the last vaccination. -
Exclusion Criteria:
- Treatment with non-cART regimen prior to cART regimen;
- Previous failure to antiretroviral and/or mutations conferring genotypic resistance to antiretroviral therapy;
- Non-subtype B HIV infection;
- Active Hepatitis B virus and/or Hepatitis C virus co-infection;
- History of a CDC class C event (see appendix A);
- Pregnant female (screened with a positive pregnancy test), lactating or intending to become pregnant during the study;
- Active malignancy ≤ 30 days (extended period on the clinical assessment of the investigator) prior to screening;
- Active infection with fever (38°C or above) ≤ 10 days of screening and/or first vaccination;
- Therapy with immunomodulatory agents (e.g. systemic corticosteroids), including cytokines (e.g. IL-2), immunoglobulins and/or cytostatic chemotherapy ≤ 90 days prior to screening. This does not include seasonal influenza, hepatitis B and/or other travel related vaccines;
- Congenital, acquired or induced coagulation disorders, such as thrombocytopenia (thrombocytes < 150x109/L) and/or current use of anti-coagulant medication (e.g. coumarins, inhibitors of Xa); Usage of NSAIDs (including acetylsalicylic acid) is allowed, however it is advised to interrupt therapy 10 days ahead of vaccination;
- Usage of any investigational drug ≤ 90 days prior to study entry;
- An employee of the investigator or study site, with direct involvement in the proposed study or other studies under the direction of that investigator or study site, or is a family member of an employee or the investigator Any other condition, which, in the opinion of the investigator, may interfere with the evaluation of the study objectives
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: iHIVARNA-01
Biological: 1200μg mRNA (900 μg HIV mRNA+300 μg TriMix mRNA) 3 vaccinations, two weeks interval
|
Therapeutic vaccination, followed by treatment interruption
Other Names:
Therapeutic vaccination, followed by treatment interruption
|
Active Comparator: TriMix
Biological: TriMix_300 μg TriMix mRNA 3 vaccinations, two weeks interval
|
Therapeutic vaccination, followed by treatment interruption
|
Placebo Comparator: Placebo
Water for injection 3 vaccinations, two weeks interval
|
Therapeutic vaccination, followed by treatment interruption
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0
Time Frame: week 6
|
Any event attributable to vaccination leading to discontinuation of the immunisation regimen. |
week 6
|
Immunogenicity as Measured by Elispot
Time Frame: week 6 and week 18
|
Change from baseline immunogenicity as measured by ELISPOT at week 6 and 18, i.e. two weeks and 14 weeks after the last immunization compared to both control groups
|
week 6 and week 18
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Immunogenicity as Measured by Intracellular Cytokine Staining (ICS)
Time Frame: week 10, 18 and 30
|
HIV-specific CD4+ and CD8+ T cell responses after immunization by the number of poly-functional T cells as determined by intracellular cytokine staining, (ICS).
|
week 10, 18 and 30
|
Time to Viral Rebound
Time Frame: week 6-18
|
time until viral rebound (defined as two consecutive measurements of plasma viral load > 1000 copies/mL separated by at least 15 days) after discontinuation at week 6.
|
week 6-18
|
Change in Plasma Viral Load
Time Frame: week 6-18
|
difference in log10 copies/ml plasma viral load in vivo after analytical treatment interruption (ATI, week 6-restart ART), compared to placebo WFI
|
week 6-18
|
Functional Cure
Time Frame: week 18
|
proportion of patients with viral load below detectable level of 50 copies/mL in plasma after ATI, week 18
|
week 18
|
Primary Immune Response Against Vaccine
Time Frame: from baseline to week 6
|
Change in frequency of at least 0.7log10 HIV-specific T-cell responses between baseline and week 6
|
from baseline to week 6
|
CD8 T Cell Mediated Viral Suppression
Time Frame: week 4
|
The capacity of CD8 T cells to suppress virus production in HIV infected autologous CD4 T cells, after vaccination.
For this purpose PBMC are isolated and separated in CD8 and CD4 T cells.
CD4 cells are infected with HIV.
Thereafter CD4 cells are co-cultured with pre-stimulated CD8 cells and the capacity to suppress virus production at different effector to target (E:T) ratios is measured, by the change of p24 Gag production.
Pannus et al AIDS 2019, PMID: 30702513
|
week 4
|
Proviral DNA Reservoir
Time Frame: day 0-90 (week 4, week 4 + 1 day and week 5 and week 6) and day 90-130 (week 18) and day >130 (week 30)
|
effect on reservoir as measured by changes in the proviral DNA copy numbers per million cells during and after immunization
|
day 0-90 (week 4, week 4 + 1 day and week 5 and week 6) and day 90-130 (week 18) and day >130 (week 30)
|
Viral Immune Escape
Time Frame: week 18
|
viral immune escape: change in % mutated epitopes from pre-cART to post-ATI
|
week 18
|
Transcriptomics
Time Frame: week 6 and 18
|
host protein mRNA expression profiles in whole blood
|
week 6 and 18
|
Cell-associated RNA Viral Reservoir
Time Frame: day 0-30 (week 4, week 4 + 1 day and week 5) and day 30-80 (week 6), 80-150 days (week 18) and >150 days (week 30)
|
effect on reservoir as measured by changes in the intracellular viral RNA copy numbers per million cells during and after immunization
|
day 0-30 (week 4, week 4 + 1 day and week 5) and day 30-80 (week 6), 80-150 days (week 18) and >150 days (week 30)
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Rob A Gruters, PhD, Erasmus Medical Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- iHIVARNA phase II
- 2016-002724-83 (EudraCT Number)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infections
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of California, San DiegoUniversity of California, Los Angeles; University of Southern California; California... and other collaboratorsCompleted
-
Gérond'ifRecruiting
-
University of California, DavisCompleted
-
University of California, San DiegoNational Center for Complementary and Integrative Health (NCCIH)CompletedHIV PositiveUnited States
-
University of ChicagoUniversity of Athens; National Development and Research Institutes, Inc.Completed
-
HIV Prevention Trials NetworkNational Institute on Drug Abuse (NIDA); National Institute of Allergy and...CompletedHIV PositiveIndonesia, Ukraine, Vietnam
-
University of ZimbabweCompleted
-
Florida International UniversityCompleted
-
Boston Children's HospitalNational Institute on Minority Health and Health Disparities (NIMHD)Completed
Clinical Trials on iHIVARNA-01
-
Judit Pich MartínezCompleted
-
Livzon Pharmaceutical Group Inc.Active, not recruiting
-
Zucara Therapeutics Inc.RecruitingType 1 Diabetes Mellitus With HypoglycemiaUnited States, Canada
-
Ixchelsis LimitedCompletedPremature EjaculationUnited States
-
Shanghai Hongyitang Biopharmaceutical Technology...Completed
-
Enterin Inc.TerminatedParkinson Disease | ConstipationUnited States
-
Zhongmou TherapeuticsRecruitingX-linked RetinoschisisChina
-
BioPharmX, Inc.CompletedAcne VulgarisUnited States
-
Enterin Inc.CompletedParkinson Disease | ConstipationUnited States
-
Shenzhen Yangli Pharmaceutical Technology Co., LtdRecruiting